The U.S. Food and Drug Administration (FDA) has given permission for Angion Biomedica to launch a Phase clinical 1b trial to test its experimental anti-fibrotic medication ANG-3070 in people with idiopathic pulmonary fibrosis (IPF). Angion is planning to launch the trial soon and expects that results will be available before the year’s end.